JP2015527402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527402A5 JP2015527402A5 JP2015531261A JP2015531261A JP2015527402A5 JP 2015527402 A5 JP2015527402 A5 JP 2015527402A5 JP 2015531261 A JP2015531261 A JP 2015531261A JP 2015531261 A JP2015531261 A JP 2015531261A JP 2015527402 A5 JP2015527402 A5 JP 2015527402A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- adalimumab
- concentration
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- 229960002964 adalimumab Drugs 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 10
- 229920005862 polyol Polymers 0.000 claims 8
- 150000003077 polyols Chemical class 0.000 claims 8
- 229910019142 PO4 Inorganic materials 0.000 claims 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 7
- 239000010452 phosphate Substances 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000003381 stabilizer Substances 0.000 claims 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 3
- 235000011152 sodium sulphate Nutrition 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698138P | 2012-09-07 | 2012-09-07 | |
| US61/698,138 | 2012-09-07 | ||
| US201361769581P | 2013-02-26 | 2013-02-26 | |
| US61/769,581 | 2013-02-26 | ||
| US201361770421P | 2013-02-28 | 2013-02-28 | |
| US61/770,421 | 2013-02-28 | ||
| PCT/US2013/058618 WO2014039903A2 (en) | 2012-09-07 | 2013-09-06 | Stable aqueous formulations of adalimumab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018244382A Division JP6783845B2 (ja) | 2012-09-07 | 2018-12-27 | 安定水性アダリムマブ製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527402A JP2015527402A (ja) | 2015-09-17 |
| JP2015527402A5 true JP2015527402A5 (enExample) | 2016-10-27 |
| JP6463268B2 JP6463268B2 (ja) | 2019-01-30 |
Family
ID=50237778
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531261A Expired - Fee Related JP6463268B2 (ja) | 2012-09-07 | 2013-09-06 | 安定水性アダリムマブ製剤 |
| JP2018244382A Expired - Fee Related JP6783845B2 (ja) | 2012-09-07 | 2018-12-27 | 安定水性アダリムマブ製剤 |
| JP2020176477A Ceased JP2021020930A (ja) | 2012-09-07 | 2020-10-21 | 安定水性アダリムマブ製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018244382A Expired - Fee Related JP6783845B2 (ja) | 2012-09-07 | 2018-12-27 | 安定水性アダリムマブ製剤 |
| JP2020176477A Ceased JP2021020930A (ja) | 2012-09-07 | 2020-10-21 | 安定水性アダリムマブ製剤 |
Country Status (31)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140186361A1 (en) | 2012-09-07 | 2014-07-03 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Adalimumab |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| KR20160105535A (ko) | 2012-03-07 | 2016-09-06 | 카딜라 핼쓰캐어 리미티드 | TNF-α 항체의 약제학적 제형 |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| WO2014114651A1 (en) * | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| AU2014337263B2 (en) | 2013-10-16 | 2019-12-12 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| CA2944330A1 (en) | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| PL2946765T3 (pl) * | 2014-05-23 | 2017-08-31 | Ares Trading S.A. | Ciekła kompozycja farmaceutyczna |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| KR20170018810A (ko) | 2014-06-10 | 2017-02-20 | 메이지 세이카 파루마 가부시키가이샤 | 안정한 아달리무맙 수성 제제 |
| US9821059B2 (en) * | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
| HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
| EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| EP3250598A1 (en) * | 2015-01-28 | 2017-12-06 | Mabxience S.A. | Pharmaceutical formulations for anti-tnf-alpha antibodies |
| EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
| US20180008707A1 (en) * | 2015-02-13 | 2018-01-11 | Sanofi | Stable liquid formulation for monoclonal antibodies |
| WO2016162819A1 (en) | 2015-04-07 | 2016-10-13 | Lupin Limited | Stable aqueous pharmaceutical composition of anti-tnf alpha antibody |
| US11583584B1 (en) * | 2015-10-28 | 2023-02-21 | Coherus Biosciences, Inc. | Stable protein compositions and methods of their use |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| BR112018014123A2 (pt) * | 2016-01-12 | 2018-12-11 | Dr. Reddy's Laboratories Limited | formulação farmacêutica aquosa estável. |
| EP3411401A1 (en) * | 2016-02-03 | 2018-12-12 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| BR112018017031A2 (pt) | 2016-02-23 | 2019-01-22 | Sesen Bio Inc | formulações de antagonista de il-6 e usos das mesmas |
| ES2962373T3 (es) * | 2016-04-13 | 2024-03-18 | Medimmune Llc | Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| US20180043020A1 (en) * | 2016-04-20 | 2018-02-15 | Coherus Biosciences, Inc. | Method of reducing immunogenicity of drug products |
| UA122610C2 (uk) | 2016-06-30 | 2020-12-10 | Селлтріон Інк. | Стабільний рідкий фармацевтичний склад |
| KR20180046888A (ko) * | 2016-10-28 | 2018-05-09 | (주)셀트리온 | 안정한 약제학적 제제 |
| EP3824906A1 (en) * | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372242A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| NZ757965A (en) * | 2017-03-16 | 2022-07-01 | Lg Chemical Ltd | Liquid formulation of anti-tnf alpha antibody |
| WO2018184693A1 (en) * | 2017-04-07 | 2018-10-11 | Ares Trading S.A. | Liquid pharmaceutical composition |
| WO2018184692A1 (en) * | 2017-04-07 | 2018-10-11 | Ares Trading S.A. | Liquid pharmaceutical composition |
| WO2019060062A1 (en) * | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals Inc. | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM |
| PT3684407T (pt) * | 2017-09-20 | 2026-03-30 | Alvotech Hf | Formulações farmacêuticas para adalimumab |
| RU2020131642A (ru) | 2018-03-29 | 2022-04-29 | Эйрвэй Терапьютикс, Инк. | Способы и композиции, содержащие сурфактантный белок d (sp-d) |
| AU2020207124A1 (en) * | 2019-01-11 | 2021-07-29 | Samsung Bioepis Co., Ltd. | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
| PE20212185A1 (es) * | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| CN113727730A (zh) * | 2019-03-18 | 2021-11-30 | 阿尔沃科技Hf公司 | 高浓度TNFα抗体的含水制剂 |
| JP7792137B2 (ja) * | 2019-08-30 | 2025-12-25 | カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー | 高濃度の薬理学的に活性な抗体の新規製剤 |
| TW202535466A (zh) | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| CU20190104A7 (es) * | 2019-12-17 | 2021-08-06 | Ct Inmunologia Molecular | Formulación estable del anticuerpo nimotuzumab |
| US20230151102A1 (en) * | 2020-01-13 | 2023-05-18 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
| US20230173068A1 (en) * | 2020-02-20 | 2023-06-08 | Bio-Thera Solutions, Ltd. | ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF |
| US20230115267A1 (en) * | 2020-03-13 | 2023-04-13 | Samsung Bioepis Co., Ltd. | Pharmaceutical liquid composition having increased stability |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2021234584A1 (en) * | 2020-05-21 | 2021-11-25 | Shilpa Biologicals Private Limited | Pharmaceutical compositions comprising adalimumab |
| RU2745814C1 (ru) * | 2020-06-05 | 2021-04-01 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция левилимаба и ее применение |
| WO2022187834A1 (en) * | 2021-03-03 | 2022-09-09 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| TW202304509A (zh) * | 2021-04-02 | 2023-02-01 | 合一生技股份有限公司 | 高濃度抗體製劑 |
| US20240366757A1 (en) * | 2021-09-07 | 2024-11-07 | Dr. Reddy’S Laboratories Limited | Formulations of immune check point inhibitors or like |
| KR20240073051A (ko) * | 2021-09-16 | 2024-05-24 | 주식회사 에이프로젠 | 항-TNFα 항체를 포함하는 약제학적 조성물 |
| CN114788809B (zh) * | 2022-01-25 | 2023-04-14 | 江苏广承药业有限公司 | 一种氯雷他定液体制剂 |
| WO2023183898A1 (en) * | 2022-03-24 | 2023-09-28 | Arch Oncology, Inc. | Formulations for anti-cd47 antibodies |
| WO2025038671A2 (en) * | 2023-08-15 | 2025-02-20 | Amgen Inc. | Acidic buffered intravenous solution stabilizers for use in methods of treatment |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| US5104651A (en) | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
| US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| AU2989695A (en) | 1994-08-08 | 2000-03-07 | Debiopharm S.A. | Pharmaceutically stable oxaliplatinum preparation |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6171576B1 (en) | 1995-11-03 | 2001-01-09 | Organix Inc. | Dopamine transporter imaging agent |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| JP2000516594A (ja) | 1996-07-26 | 2000-12-12 | スミスクライン・ビーチャム・コーポレイション | 免疫細胞介在全身性疾患の改良された治療法 |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE230277T1 (de) * | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
| US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| US6171686B1 (en) | 1997-10-03 | 2001-01-09 | Marine Environmental Solutions, L.L.C. | Synthetic aquatic structure |
| ES2179414T3 (es) | 1997-11-22 | 2003-01-16 | Roche Diagnostics Gmbh | Procedimiento mejorado de estabilizacion de proteinas. |
| AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| DK2270044T3 (en) | 1998-06-09 | 2015-01-26 | Csl Behring Ag | Liquid immunoglobulin G (IgG) product |
| BR0009323A (pt) | 1999-03-25 | 2002-01-08 | Knoll Gmbh | Anticorpos humanos que ligam a il-12 humana e métodos para a produção |
| KR100740794B1 (ko) | 1999-04-09 | 2007-07-20 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 에리트로포이에틴의 약제학적 제형 |
| AUPQ026799A0 (en) | 1999-05-10 | 1999-06-03 | Csl Limited | Method of increasing protein stability by removing immunoglobulin aggregates |
| JP4516711B2 (ja) * | 1999-12-28 | 2010-08-04 | 中外製薬株式会社 | 安定な抗体組成物及び注射製剤 |
| AU2001276737A1 (en) | 2000-08-04 | 2002-02-18 | Chugai Seiyaku Kabushiki Kaisha | Protein injection preparations |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| US20140186361A1 (en) | 2012-09-07 | 2014-07-03 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Adalimumab |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| CA2476934C (en) | 2002-02-27 | 2009-06-16 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| AU2003249992A1 (en) | 2002-07-09 | 2004-01-23 | Sandoz Ag | Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| CA2504134C (en) | 2002-11-01 | 2012-03-06 | Bayer Healthcare Llc | Process for concentration of macromolecules |
| FR2853551B1 (fr) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
| WO2005063291A1 (ja) * | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
| WO2006022599A1 (en) | 2004-08-27 | 2006-03-02 | Marian Metke | Production method for exfoliated graphite, equipment for its production, exfoliated graphite and means of its use |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| US7705132B2 (en) | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
| KR101540823B1 (ko) * | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| WO2008135380A1 (en) | 2007-05-02 | 2008-11-13 | F. Hoffmann-La Roche Ag | Method for stabilizing a protein |
| WO2009015345A1 (en) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| US20090151807A1 (en) | 2007-08-07 | 2009-06-18 | Davis Chanda Janese | Container Insert for Zero Headspace |
| US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US20130195888A1 (en) | 2007-11-30 | 2013-08-01 | Abbvie | Ultrafiltration and diafiltration formulation methods for protein processing |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| WO2009073805A2 (en) | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| SG2013054218A (en) * | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| CA2932207A1 (en) * | 2008-10-20 | 2010-12-09 | Abbvie Inc. | Isolation and purification of antibodies using protein a affinity chromatography |
| MX2011005672A (es) | 2008-11-28 | 2011-06-20 | Abbott Lab | Composiciones de anticuerpo estables y metodos para estabilizar a las mismas. |
| US20110236391A1 (en) | 2008-12-09 | 2011-09-29 | Hanns-Christian Mahler | Method for obtaining an excipient-free antibody solution |
| US20100278822A1 (en) | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| PL3721904T3 (pl) | 2009-11-20 | 2022-01-31 | Biocon Limited | Formulacje przeciwciała t1h |
| US20110158987A1 (en) * | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
| SG184355A1 (en) * | 2010-03-01 | 2012-11-29 | Progenics Pharm Inc | Concentrated protein formulations and uses thereof |
| RU2600847C2 (ru) | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
| FR2961107B1 (fr) | 2010-06-15 | 2012-07-27 | Lab Francais Du Fractionnement | Composition d'immunoglobulines humaines stabilisee |
| CH703405B1 (de) | 2010-07-05 | 2014-05-15 | Melexis Tessenderlo Nv | Magnetischer Winkelsensor. |
| ES2665954T3 (es) * | 2010-08-19 | 2018-04-30 | Zoetis Belgium S.A. | Anticuerpos anti-NGF y su uso |
| PL2616090T3 (pl) * | 2010-09-17 | 2023-12-18 | Takeda Pharmaceutical Company Limited | Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego |
| TWI603739B (zh) | 2010-11-11 | 2017-11-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物 |
| EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| RU2614257C2 (ru) | 2011-04-20 | 2017-03-24 | Сандоз Аг | СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc |
| US20150182525A1 (en) | 2011-05-19 | 2015-07-02 | Novartis Ag | 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Quinolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| EA026226B1 (ru) | 2011-07-01 | 2017-03-31 | Байоджен Айдек Ма Инк. | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| WO2013096835A1 (en) | 2011-12-23 | 2013-06-27 | Abbvie Inc. | Stable protein formulations |
| KR20160105535A (ko) | 2012-03-07 | 2016-09-06 | 카딜라 핼쓰캐어 리미티드 | TNF-α 항체의 약제학적 제형 |
| EP2863951A1 (en) | 2012-06-12 | 2015-04-29 | Boehringer Ingelheim International GmbH | Pharmaceutical formulation for a therapeutic antibody |
| US20150102042A1 (en) | 2012-07-10 | 2015-04-16 | Gary Matsch | Air Purging Lid |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| CN102988984B (zh) | 2012-12-21 | 2015-05-20 | 嘉和生物药业有限公司 | 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂 |
| WO2014186230A1 (en) | 2013-05-13 | 2014-11-20 | Endochoice, Inc. | An endoscope tip position visual indicator and heat management system |
| US9681695B2 (en) | 2013-07-31 | 2017-06-20 | Sport Maska Inc. | Helmet with chin cup |
-
2013
- 2013-09-06 US US14/020,733 patent/US20140186361A1/en not_active Abandoned
- 2013-09-06 SI SI201331693T patent/SI2892550T1/sl unknown
- 2013-09-06 CN CN201380058126.8A patent/CN104768576A/zh active Pending
- 2013-09-06 KR KR1020157008873A patent/KR102238677B1/ko not_active Expired - Fee Related
- 2013-09-06 PT PT138352919T patent/PT2892550T/pt unknown
- 2013-09-06 PE PE2015000306A patent/PE20150964A1/es not_active Application Discontinuation
- 2013-09-06 HR HRP20200434TT patent/HRP20200434T1/hr unknown
- 2013-09-06 KR KR1020217010005A patent/KR102362829B1/ko not_active Expired - Fee Related
- 2013-09-06 MX MX2015003007A patent/MX2015003007A/es unknown
- 2013-09-06 TW TW109103597A patent/TW202042841A/zh unknown
- 2013-09-06 RS RS20200310A patent/RS60226B1/sr unknown
- 2013-09-06 EA EA201791717A patent/EA201791717A1/ru unknown
- 2013-09-06 SG SG10201705668XA patent/SG10201705668XA/en unknown
- 2013-09-06 EP EP13835291.9A patent/EP2892550B1/en active Active
- 2013-09-06 CA CA3153799A patent/CA3153799A1/en active Pending
- 2013-09-06 DK DK13835291.9T patent/DK2892550T3/da active
- 2013-09-06 PE PE2019002434A patent/PE20191815A1/es unknown
- 2013-09-06 ES ES13835291T patent/ES2784861T3/es active Active
- 2013-09-06 AR ARP130103178A patent/AR092470A1/es not_active Application Discontinuation
- 2013-09-06 LT LTEP13835291.9T patent/LT2892550T/lt unknown
- 2013-09-06 AU AU2013312300A patent/AU2013312300A1/en not_active Abandoned
- 2013-09-06 HU HUE13835291A patent/HUE049282T2/hu unknown
- 2013-09-06 SM SM20200147T patent/SMT202000147T1/it unknown
- 2013-09-06 JP JP2015531261A patent/JP6463268B2/ja not_active Expired - Fee Related
- 2013-09-06 EA EA201590518A patent/EA029215B1/ru unknown
- 2013-09-06 WO PCT/US2013/058618 patent/WO2014039903A2/en not_active Ceased
- 2013-09-06 TW TW102132360A patent/TWI698253B/zh not_active IP Right Cessation
- 2013-09-06 CA CA2884182A patent/CA2884182C/en active Active
- 2013-09-06 KR KR1020227004460A patent/KR20220025196A/ko not_active Ceased
- 2013-09-06 BR BR112015004984A patent/BR112015004984A2/pt active Search and Examination
- 2013-09-06 PL PL13835291T patent/PL2892550T3/pl unknown
- 2013-09-06 EP EP19216514.0A patent/EP3701968A1/en not_active Withdrawn
- 2013-09-06 SG SG11201501715QA patent/SG11201501715QA/en unknown
-
2014
- 2014-02-26 UY UY0001035351A patent/UY35351A/es not_active Application Discontinuation
-
2015
- 2015-03-05 IL IL237583A patent/IL237583B/en active IP Right Review Request
- 2015-03-06 DO DO2015000051A patent/DOP2015000051A/es unknown
- 2015-03-06 CL CL2015000574A patent/CL2015000574A1/es unknown
- 2015-03-10 US US14/643,844 patent/US9340611B2/en not_active Expired - Fee Related
- 2015-03-18 US US14/661,899 patent/US9346880B2/en not_active Expired - Fee Related
- 2015-03-18 US US14/661,849 patent/US9782479B2/en not_active Expired - Fee Related
- 2015-03-18 US US14/661,288 patent/US9340612B2/en not_active Expired - Fee Related
- 2015-03-18 US US14/661,938 patent/US9382317B2/en not_active Expired - Fee Related
- 2015-04-06 EC ECIEPI201513227A patent/ECSP15013227A/es unknown
- 2015-10-09 US US14/879,885 patent/US9808525B2/en not_active Expired - Fee Related
- 2015-10-09 US US14/879,847 patent/US9724414B2/en not_active Expired - Fee Related
-
2016
- 2016-05-16 US US15/155,982 patent/US9789185B2/en not_active Expired - Fee Related
- 2016-05-16 US US15/155,832 patent/US9682145B2/en not_active Expired - Fee Related
- 2016-05-16 US US15/155,925 patent/US9707293B2/en active Active
- 2016-05-23 US US15/162,140 patent/US9757454B2/en not_active Expired - Fee Related
- 2016-06-27 US US15/193,523 patent/US9731009B2/en not_active Expired - Fee Related
- 2016-06-27 US US15/193,415 patent/US9737600B2/en not_active Expired - Fee Related
- 2016-06-27 US US15/193,345 patent/US9770507B2/en not_active Expired - Fee Related
- 2016-06-27 US US15/193,387 patent/US9731008B2/en not_active Expired - Fee Related
- 2016-06-27 US US15/193,454 patent/US9782480B2/en not_active Expired - Fee Related
- 2016-06-27 US US15/193,486 patent/US9724415B2/en not_active Expired - Fee Related
- 2016-11-23 US US15/360,678 patent/US9861695B2/en not_active Expired - Fee Related
-
2017
- 2017-07-18 US US15/653,228 patent/US10780163B2/en active Active
- 2017-08-15 US US15/677,857 patent/US10786566B2/en active Active
- 2017-10-05 US US15/726,195 patent/US10207000B2/en active Active
- 2017-10-05 US US15/726,165 patent/US10159732B2/en active Active
- 2017-10-05 US US15/726,215 patent/US10159733B2/en active Active
- 2017-10-10 US US15/729,243 patent/US10286071B2/en active Active
- 2017-10-10 US US15/729,295 patent/US10286072B2/en active Active
- 2017-10-11 US US15/730,425 patent/US20180028656A1/en not_active Abandoned
- 2017-10-11 US US15/730,445 patent/US20180028657A1/en not_active Abandoned
- 2017-10-11 US US15/730,399 patent/US20180028655A1/en not_active Abandoned
- 2017-10-31 US US15/799,851 patent/US10155039B2/en active Active
-
2018
- 2018-01-09 US US15/866,154 patent/US10195275B2/en active Active
- 2018-06-29 US US16/023,161 patent/US10799585B2/en active Active
- 2018-06-29 US US16/023,152 patent/US10772960B2/en active Active
- 2018-06-29 US US16/023,205 patent/US10688183B2/en not_active Expired - Fee Related
- 2018-06-29 US US16/023,046 patent/US10772959B2/en active Active
- 2018-07-26 AU AU2018208699A patent/AU2018208699A1/en not_active Abandoned
- 2018-11-01 US US16/178,309 patent/US10716853B2/en not_active Expired - Fee Related
- 2018-11-01 US US16/178,319 patent/US10716854B2/en not_active Expired - Fee Related
- 2018-11-01 US US16/178,137 patent/US10722579B2/en not_active Expired - Fee Related
- 2018-11-01 US US16/178,164 patent/US10716852B2/en not_active Expired - Fee Related
- 2018-12-27 JP JP2018244382A patent/JP6783845B2/ja not_active Expired - Fee Related
-
2020
- 2020-03-18 CY CY20201100247T patent/CY1123407T1/el unknown
- 2020-05-01 AU AU2020202912A patent/AU2020202912A1/en not_active Abandoned
- 2020-09-29 IL IL277652A patent/IL277652B2/en unknown
- 2020-10-21 JP JP2020176477A patent/JP2021020930A/ja not_active Ceased